从基金十大重仓股角度 数据显示，国海富兰克林基金旗下1只基金重仓药明康德。国富中证A100指数增强(LOF)（164508）二 季度持有股数1.12万股，占基金净值比例为2.28%，位居第十大重仓股。根据测算，今日浮盈赚取约 6.03万元。 9月30日，药明康德涨5.11%，截至发稿，报110.65元/股，成交36.38亿元，换手率1.35%，总市值 3265.84亿元。 资料显示，无锡药明康德新药开发股份有限公司位于上海浦东新区外高桥保税区富特中路288号,香港铜 锣湾希慎道33号利园1期19楼1910室，成立日期2000年12月1日，上市日期2018年5月8日，公司主营业务 涉及小分子化学药的发现、研发及生产全方位、一体化平台服务,以全产业链平台的形式面向全球制药 企业提供各类新药的研发、生产及配套服务。主营业务收入构成为：化学业务78.37%，测试业务 12.93%，生物学业务6.02%，其他(补充)1.90%，其他业务0.79%。 截至发稿，张志强累计任职时间12年197天，现任基金资产总规模4.51亿元，任职期间最佳基金回报 125.94%， 任职期间最差基金回报5.8%。 风险提示：市场有风险，投 ...

9月30日早盘，药明康德AH股齐涨，均涨逾5%。截至10:02，双双涨超5%。 ...

Summary of WuXi AppTec Co Ltd Investor Day Company Overview - **Company**: WuXi AppTec Co Ltd - **Industry**: Contract Development and Manufacturing Organizations (CDMOs) - **Date of Investor Day**: September 29, 2025 - **Location**: Changzhou, Jiangsu province, China Key Points Industry Insights 1. **R&D Pipeline Contribution**: Small molecules and synthetic new modalities are the mainstay of global R&D, contributing 54% of pipeline candidates in 2024 [2] 2. **Innovation from Small Biopharma**: The share of global R&D spending by small biopharma companies increased from 17% in 2015 to 20% in 2024, projected to reach 26% by 2030 [2] 3. **Venture Capital Funding**: Small molecules received 37% of venture capital funding from 2022 to mid-2025, followed by biologics at 26% and cell/gene therapies at 17% [3] 4. **China's Biopharma Ecosystem**: China's early-stage biopharma companies are approximately half of those in the US, indicating a growing innovation ecosystem [4] 5. **Outsourcing Trends**: The global outsourcing rate to Contract Research Organizations (CROs) rose from 35% in 2015 to 52% in 2024, projected to reach 62% by 2030 [4] Company Performance 6. **Molecular Complexity**: WuXi AppTec's contracts showed increased molecular complexity from 2021 to 2025, with a 22% rise in synthetic steps for long-route molecules and a 63% increase in the proportion of molecules weighing over 600 Daltons [4] 7. **Customer Utilization**: Approximately one-third of active customers in oncology, infectious disease, immunology, metabolic disease, and neuroscience utilize WuXi's discovery services [4] 8. **FDA Approvals**: WuXi produced 20% of novel small molecule drugs approved by the US FDA from 2024 to mid-2025, totaling 8 out of 40 approved drugs [4] Market Position 9. **GLP-1 Contracts**: WuXi currently holds 23 GLP-1 contracts, translating to a 24% market share of pipeline drugs by number [5] 10. **Licensing and M&A Activity**: Of 213 licensing and M&A deals for synthetic drugs globally from 2024 to mid-2025, 62 (or 29%) involved WuXi's customers [5] Financial Metrics 11. **Stock Rating**: The stock is rated as Overweight with a price target of HK$106.00, showing a slight downside from the current price of HK$107.60 [7] 12. **Market Capitalization**: The current market cap is approximately RMB 296.437 billion [7] 13. **Revenue Growth**: Projected revenue growth from RMB 39.241 billion in 2024 to RMB 58.491 billion by 2027 [7] 14. **Earnings Per Share (EPS)**: Expected EPS growth from RMB 3.23 in 2024 to RMB 5.87 in 2027 [7] Risks and Opportunities 15. **Upside Risks**: Potential inflection of Fed rates could lead to increased biotech funding, along with favorable government policies and margin expansion [41] 16. **Downside Risks**: Risks include talent turnover, margin pressure from US business, global competition, and geopolitical risks [41] Conclusion WuXi AppTec is positioned strongly within the CDMO sector, with significant contributions to the global R&D landscape and a robust pipeline of contracts. The company is navigating a competitive environment while capitalizing on growth opportunities in the biopharma space.

Core Viewpoint - WuXi AppTec's stock price has shown significant growth this year, with a year-to-date increase of 101.41%, indicating strong market performance and investor interest [1][2]. Financial Performance - For the first half of 2025, WuXi AppTec reported revenue of 20.799 billion yuan, a year-on-year increase of 20.64%, and a net profit attributable to shareholders of 8.561 billion yuan, which represents a remarkable growth of 101.92% [2]. - The company has distributed a total of 14.06 billion yuan in dividends since its A-share listing, with 10.406 billion yuan distributed over the past three years [3]. Stock Market Activity - As of September 30, WuXi AppTec's stock price was 107.47 yuan per share, with a market capitalization of 317.198 billion yuan. The stock experienced a net inflow of 12.9546 million yuan from major funds [1]. - The trading volume on September 30 was 544 million yuan, with a turnover rate of 0.21% [1]. Shareholder Information - As of June 30, 2025, WuXi AppTec had 235,500 shareholders, with the average circulating shares per person remaining at zero [2]. - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 302 million shares, an increase of 56.0239 million shares from the previous period [3].

Group 1 - A total of 26 buy ratings were issued by institutions today, covering 25 stocks, with WuXi AppTec receiving the highest attention with 2 buy ratings [1][2] - Among the buy ratings, 7 were first-time ratings for stocks including Anfu Technology and Huadian Co., Ltd [1] - The average increase for stocks with buy ratings was 2.19%, outperforming the Shanghai Composite Index, with 23 stocks rising and some hitting the daily limit [1] Group 2 - The pharmaceutical and biotechnology sector was the most favored, with five stocks including WuXi AppTec and Meihua Medical receiving buy ratings [1] - The electronics and communications sectors also attracted institutional interest, with 4 and 3 stocks respectively receiving buy ratings [1]

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 002622 | 皓宸医疗 | 3.21 | -6.96% | 91.76万 | 2.95 Z | | 603127 | 昭衍新药 | 35.31 | -4.39% | 32.87万 | 11.51亿 | | 688046 | 药康生物 | 17.66 | -4.13% | 3.39万 | 6034.58万 | | 688131 | 皓元医药 | 77.66 | -1.97% | 4.39万 | 3.40亿 | | 000504 | *ST生物 | 9.16 | -1.72% | 2.36万 | 2169.47万 | | 835670 | 数字人 | 15.37 | -1.54% | 2.52万 | 3907.47万 | | 688073 | 毕得医药 | 75.92 | -1.27% | 8913.84 | 6690.90万 | | 688710 | 益诺恩 | 46.80 | -1.24% | 9044.18 | 4239.32万 | | 60 ...

Core Viewpoint - Bank of America Securities has raised its revenue forecasts for WuXi AppTec (02359) for 2026 and 2027 by 0.2% and 0.3% respectively, citing better-than-expected prospects in its biological and chemical businesses [1] Group 1: Financial Projections - The earnings per share forecast has been increased by 0.4% and 0.8% due to enhanced project values and improved production efficiency [1] - The target price for WuXi AppTec has been raised from HKD 123 to HKD 130.7, maintaining a "Buy" rating [1] Group 2: Market Position and Performance - Since 2021, WuXi AppTec has maintained a 33% market share in the oncology drug development sector among active clients, which includes drug discovery and preclinical stage clients [1] - Revenue from non-oncology in vivo pharmacology business has grown by 42% in the first half of this year [1] - Despite intensified price competition in the industry, the value of new preclinical orders has increased by 14.5% year-on-year [1] - WuXi's chemical business has served approximately 2,550 clients as of the first half of the year, with management expecting revenue growth to exceed 20% for the year [1]

Core Viewpoint - Bank of America Securities has raised its revenue forecasts for WuXi AppTec (02359) for 2026 and 2027 by 0.2% and 0.3% respectively, citing better-than-expected prospects in its biological and chemical businesses [1] Group 1: Financial Projections - The gross margin forecast has been increased due to enhanced project values and improved production efficiency, leading to an upward revision of earnings per share by 0.4% and 0.8% [1] - The target price for WuXi AppTec has been raised from HKD 123 to HKD 130.7, with a reiterated "Buy" rating [1] Group 2: Market Position and Performance - Since 2021, WuXi AppTec has maintained a 33% market share in the oncology drug development sector among active clients, which includes drug discovery and preclinical stage clients [1] - Revenue from non-oncology in vivo pharmacology business grew by 42% in the first half of this year [1] - Despite intensified price competition in the industry, the value of new preclinical orders still increased by 14.5% year-on-year [1] - As of the first half of the year, WuXi AppTec's chemical business served approximately 2,550 clients, with management expecting revenue growth to exceed 20% for the year [1]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology sector [5]. Core Viewpoints - The acquisition of Metsera by Pfizer, valued at approximately $4.9 billion, underscores the significant potential and long-term growth prospects of the weight loss drug market, particularly in the GLP-1 segment [2][24]. - The report emphasizes the urgent demand for next-generation therapies, such as oral formulations and multi-target drugs, indicating a competitive landscape in the global GLP-1 research race [2][24]. - The Chinese weight loss drug industry is poised for growth, with a focus on companies that demonstrate strong sales execution and advanced research capabilities [3][24]. Summary by Sections Market Review - The pharmaceutical and biotechnology index fell by 2.20%, underperforming the CSI 300 index by 3.27 percentage points, ranking 24th among 31 sub-industries [1][16]. Key Company Insights - Companies to watch include Innovent Biologics (H), Heng Rui Medicine, Borui Medicine, Zhongsheng Pharmaceutical, Nawei Technology, WuXi AppTec (A+H), and Kelaiying (A+H) as they are expected to benefit from the expanding GLP-1 industry chain [3][24]. Annual Investment Strategy - The report suggests a structural selection of investment opportunities based on payment willingness and ability, focusing on three payment channels: hospital payments, out-of-pocket payments, and overseas payments [25]. - Key areas of interest include hospital policy support for innovative drugs and devices, expanding public demand for blood products, home medical devices, and the weight loss drug industry chain [25]. Company Earnings Forecast and Valuation - The report provides earnings per share (EPS) and price-to-earnings (PE) ratios for key companies, indicating a "Buy" rating for WuXi AppTec and Innovent Biologics, and an "Overweight" rating for Heng Rui Medicine [4]. Market Trends - The global weight loss drug market is experiencing rapid growth, with Pfizer's acquisition of Metsera highlighting the increasing market space associated with obesity-related health issues [28]. - The report notes that the commercialization of domestic weight loss drugs will hinge on sales capabilities and research advancements [3][24]. Important Company Announcements - Recent announcements include clinical trial updates and new drug applications from various companies, indicating ongoing innovation and development within the sector [27]. Financial Data - The basic medical insurance income for the first seven months of 2025 reached 1,684.7 billion yuan, with expenditures amounting to 1,369.7 billion yuan, reflecting the financial landscape impacting the pharmaceutical industry [30]. Price Trends - The report notes a decline in antibiotic prices and stability in cardiovascular raw material drug prices, which may influence the cost structure for pharmaceutical companies [36][43]. Conclusion - The report presents a positive outlook for the pharmaceutical and biotechnology sector, particularly in the weight loss drug market, driven by significant acquisitions and a growing demand for innovative therapies [2][24].

Core Insights - WuXi AppTec held an investor day event, highlighting the strong momentum in its TIDES business, rapid capacity expansion, and a rich pipeline [1] - Early-stage research shows signs of further recovery, which is expected to drive growth in early-stage business revenue, accounting for approximately one-third of total company revenue [1] - Enhanced operational efficiency supports the company's resilient profitability amid macro uncertainties and global capacity expansion, with adjusted gross margin and net profit margin reaching historical highs of 44.5% and 30.4% respectively in 1H25 [1] - Management expresses confidence in maintaining resilient profitability, leading to a slight upward adjustment of the target price to RMB 118.79 to reflect positive signals from global early-stage research demand [1] - The rating remains "Buy" [1]